| 論文種別 | 原著(症例報告除く) |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | Development of a Peptide-Based Photoimmunotherapy Drug Targeting PD-L1. |
| 掲載誌名 | 正式名:Molecules 略 称:Molecules ISSNコード:14203049 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 31(2),pp.302 |
| 著者・共著者 | Takuya Otani, Naoya Kondo, Ayaka Kanai, Hirofumi Hanaoka |
| 発行年月 | 2026/01 |
| 概要 | Near-infrared photoimmunotherapy (NIR-PIT) has recently attracted attention as a highly selective cancer treatment, with good treatment outcomes observed from the only antibody-based drug currently available for clinical use. However, since only a single agent is currently used clinically and the development of new antibodies is costly, exploring other therapeutic modalities is important. In this study, we investigated a novel peptide-based PIT drug targeting programmed death-ligand 1 (PD-L1), which is overexpressed in many types of cancer. The WL12 peptide, which is known to bind to PD-L1, was conjugated with the photoabsorber IRDye700DX (IR700), and its usefulness was evaluated in vitro and in vivo. In therapeutic experiments on PD-L1-positive cells, NIR-PIT with WL12-IR700 induced PIT-like morphological changes in cells and reduced cancer cell viability in an NIR light dose- and drug concentration-dependent manner. In vivo experiments showed significant suppression of tumor growth and an extended overall survival rate. These results indicate that the developed peptide-based drug can be used for PD-L1-targeted NIR-PIT. |
| DOI | 10.3390/molecules31020302 |
| PMID | 41599351 |